Trial Profile
A Phase II Study of PD-1 Inhibition for the Prevention of Colon Adenomas in Patients With Lynch Syndrome and a History of Partial Colectomy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenoma; Colon cancer; Hereditary nonpolyposis colorectal cancer
- Focus Therapeutic Use
- 09 Nov 2022 Status changed from active, no longer recruiting to discontinued.
- 14 May 2020 Status changed from suspended to active, no longer recruiting.
- 06 Aug 2019 Status changed from recruiting to suspended.